Streetbeat News

Revenues

PSX

Analysts have provided a range of ratings for Phillips 66 (NYSE:PSX) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 2.3% to $151.92. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting changing market conditions and company performance. Phillips 66 has shown solid revenue growth and strong profitability metrics, with a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

MRVI

Maravai LifeSciences (NASDAQ:MRVI) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target. Analysts have varied in their ratings, with some lowering and others raising their price targets. The company has shown positive revenue growth and strong financial metrics, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

HUBS

HubSpot (NYSE:HUBS) has received mixed analyst ratings over the past three months, with a recent decrease in the average price target by 7.69%. Despite positive revenue growth, HubSpot faces challenges with profitability and returns on equity and assets. Analysts have adjusted their ratings and price targets in response to these dynamics.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

SPRY

ARS Pharmaceuticals (NASDAQ:SPRY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $26.43. The company has shown significant revenue growth but struggles with profitability.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

DXCM

DexCom (NASDAQ:DXCM) has significantly outperformed the market over the past 15 years, with an annualized return of 26.92%. A $100 investment in DXCM 15 years ago would be worth $3,619.92 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

ARMK

Analysts have provided mixed ratings for Aramark (NYSE:ARMK), with a recent positive shift in price targets. The average 12-month price target increased by 9.48% to $39.85. Analysts have raised their ratings, reflecting a more optimistic outlook. Despite this, Aramark's financial performance shows challenges, with below-average net margin, ROE, and ROA compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

MSOS

Dan Roda from Safe Harbor Financial notes that 2023 marks the first year with fewer active cannabis business licenses by year-end compared to the start. This is due to fewer new states launching cannabis programs, indicating market maturation and economic impacts.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:49 pm

MSOS

Neil Prasad, a partner at Marcum CPA, expressed optimism about the future of the cannabis industry as the 280E tax provision is expected to be removed. This change is anticipated to increase cash flows for cannabis companies, leading to a more bullish outlook for the next business cycle.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:47 pm

MSOS

Security Bank President and CEO Stephan Paul Antonacci discussed consumer behavior, noting that while consumers may continue to purchase, they might not do so in the same quantities. This insight could have implications for consumer-focused sectors, including cannabis.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:46 pm

F

TM

TSLA

Toyota is delaying its US EV plans to 2026 due to an EV market slowdown, similar to Ford's recent actions. Despite this, Toyota remains committed to its EV goals, investing heavily in US factories. Tesla also faces challenges, missing Wall Street expectations and risking a decline in annual deliveries.

Portfolio Pulse from Upwallstreet

October 08, 2024 | 3:46 pm